{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:12:26Z","timestamp":1790817146472,"version":"4.1.0"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-1361_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Plasma renin activity (PRA) measures the rate of renin converting angiotensinogen to angiotensin I in circulation and reflects the function of renin-angiotensin-aldosterone system (RAAS). The study aimed to demonstrate the performance of the MAGLUMI Angiotensin I assay for the measurement of\u00a0PRA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1361_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The MAGLUMI Angiotensin I assay was evaluated for precision, linearity, limit of blank (LoB), limit of detection (LoD), limit of quantification (LoQ), interferences, cross-reactivity and reference intervals. It was compared to liquid chromatography tandem mass spectrometry (LC-MS\/MS) using 54 samples, and impact of clinical factors was assessed in 181 samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1361_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The assay demonstrated repeatability of 1.5\u202f%, 1.85%, and 1.6\u202f% across three different pool concentrations, with corresponding within-laboratory imprecision values of 2.0\u202f%, 2.5%, and 1.9\u202f%. The linear range was [0.10, 24.0]\u202fng\/mL. The LoB, the LoD, and the LoQ were 0.03\u202fng\/mL, 0.07\u202fng\/mL, and 0.10\u202fng\/mL, respectively. The interferences and cross-reactivity met the criterion for acceptable cross-reactivity (CR) with &lt;\u00b110\u202f%. Reference interval validation shows &lt;10\u202f% of a total of 40 healthy individuals\u2019 plasma samples falling outside the established interval for standing and lying position. The MAGLUMI assay showed excellent agreement with LC-MS\/MS for both angiotensin I (slope=1.076, intercept=0.109\u202fng\/mL\/h, r=0.987, p&lt;0.001) and plasma renin activity (slope=1.131, intercept=\u22120.386\u202fng\/mL\/h, r=0.973, p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1361_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The MAGLUMI Angiotensin I chemiluminescence immunoassay is a sensitive and reliable commercial kit for detecting plasma renin activity. The assay exhibited robust analytical performance and strong agreement with LC-MS\/MS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-1361","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:12:42Z","timestamp":1767690762000},"page":"1142-1151","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the MAGLUMI non-competitive angiotensin I chemiluminescence immunoassay for measuring renin activity in human plasma"],"prefix":"10.1515","volume":"64","author":[{"given":"Lina","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine , Shengjing Hospital of China Medical University , Shenyang , China"},{"name":"Liaoning Clinical Research Center for Laboratory Medicine , Shenyang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory , Pingshan General Hospital, Southern Medical University , Shenzhen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Research and Development Department , Shenzhen New Industries Biomedical Engineering Co., Ltd. , Shenzhen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shucai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory , Pingshan General Hospital, Southern Medical University , Shenzhen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyan","family":"Shi","sequence":"additional","affiliation":[{"name":"Research and Development Department , Shenzhen New Industries Biomedical Engineering Co., Ltd. , Shenzhen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Research and Development Department , Shenzhen New Industries Biomedical Engineering Co., Ltd. , Shenzhen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggang","family":"Fang","sequence":"additional","affiliation":[{"name":"Research and Development Department , Shenzhen New Industries Biomedical Engineering Co., Ltd. , Shenzhen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory , Pingshan General Hospital, Southern Medical University , Shenzhen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shengjing Hospital of China Medical University , Shenyang , China"},{"name":"Liaoning Clinical Research Center for Laboratory Medicine , Shenyang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2026033013262434951_j_cclm-2025-1361_ref_001","doi-asserted-by":"crossref","unstructured":"Skeggs, LTJ, Kahn, JR, Shumway, NP. The preparation and function of the hypertensin-converting enzyme. J\u00a0Exp Med 1956;103:295\u20139. https:\/\/doi.org\/10.1084\/jem.103.3.295.","DOI":"10.1084\/jem.103.3.295"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_002","unstructured":"Fountain, JH, Kaur, J, Lappin, SL. Physiology, renin angiotensin system. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"2026033013262434951_j_cclm-2025-1361_ref_003","doi-asserted-by":"crossref","unstructured":"Norwood, VF, Fernandez, LG, Tufro, A, Gomez, RA (2004). Chapter 128\u00a0\u2013\u00a0development of the renin-angiotensin system. In: Polin, RA, Fox, WW, Abman, SH, editors. Fetal and neonatal physiology, 3rd ed. W.B. Saunders; 2004:1249\u201356 pp.","DOI":"10.1016\/B978-0-7216-9654-6.50131-4"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_004","doi-asserted-by":"crossref","unstructured":"Carretero, OA, Oparil, S. Essential hypertension. Part I: definition and etiology. Circulation 2000;101:329\u201335. https:\/\/doi.org\/10.1161\/01.cir.101.3.329.","DOI":"10.1161\/01.CIR.101.3.329"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_005","doi-asserted-by":"crossref","unstructured":"Mulatero, P, Verhovez, A, Morello, F, Veglio, F. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol 2007;67:324\u201334. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02898.x.","DOI":"10.1111\/j.1365-2265.2007.02898.x"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_006","doi-asserted-by":"crossref","unstructured":"Gunnells, JCJ, McGuffin, WLJ, Johnsrude, I, Robinson, RR. Peripheral and renal venous plasma renin activity in hypertension. Ann Intern Med 1969;71:555\u201375. https:\/\/doi.org\/10.7326\/0003-4819-71-3-555.","DOI":"10.7326\/0003-4819-71-3-555"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_007","unstructured":"Nair, R, Vaqar, S, StatPearls [Internet]. Renovascular Hypertension. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551587\/ [Accessed 22 May 2023]."},{"key":"2026033013262434951_j_cclm-2025-1361_ref_008","doi-asserted-by":"crossref","unstructured":"Adler, GK, Stowasser, M, Correa, RR, Khan, N, Kline, G, McGowan, MJ, et al.. Primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J\u00a0Clin Endocrinol Metab 2025;110:2453\u201395. https:\/\/doi.org\/10.1210\/clinem\/dgaf284.","DOI":"10.1210\/clinem\/dgaf284"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_009","doi-asserted-by":"crossref","unstructured":"Rossi, GP, Rossi, FB, Guarnieri, C, Rossitto, G, Seccia, TM. Clinical management of primary aldosteronism: an update. Hypertension 2024;81:1845\u201356. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.22642.","DOI":"10.1161\/HYPERTENSIONAHA.124.22642"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_010","doi-asserted-by":"crossref","unstructured":"Ha, J, Park, JH, Kim, KJ, Jung, KY, Lee, J, Choi, JH, et al.. Korean Endocrine Society consensus guidelines for the diagnosis and management of primary aldosteronism. Endocrinol Metab (Seoul) 2023;38:597\u2013618. https:\/\/doi.org\/10.3803\/EnM.2023.1789.","DOI":"10.3803\/EnM.2023.1789"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_011","doi-asserted-by":"crossref","unstructured":"Jones, DW, Ferdinand, KC, Taler, SJ, Johnson, HM, Shimbo, D, Abdalla, M, et al., Writing Committee Members*. AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 2025;82:e212-316. https:\/\/doi.org\/10.1161\/HYP.0000000000000249.","DOI":"10.1161\/HYP.0000000000000249"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_012","doi-asserted-by":"crossref","unstructured":"Cohen, EL, Conn, JW, Rovner, DR. Postural augmentation of plasma renin activity and aldosterone excretion in normal people. J\u00a0Clin Investig 1967;46:418\u201328. https:\/\/doi.org\/10.1172\/JCI105543.","DOI":"10.1172\/JCI105543"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_013","doi-asserted-by":"crossref","unstructured":"Lamarre-Cliche, M, de Champlain, J, Lacourci\u00e8re, Y, Poirier, L, Karas, M, Larochelle, P. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J Hypertens 2005;18:56\u201364. https:\/\/doi.org\/10.1016\/j.amjhyper.2004.08.025.","DOI":"10.1016\/j.amjhyper.2004.08.025"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_014","doi-asserted-by":"crossref","unstructured":"Ohashi, N, Isobe, S, Ishigaki, S, Yasuda, H. Circadian rhythm of blood pressure and the renin-angiotensin system in the kidney. Hypertens Res 2017;40:413\u201322. https:\/\/doi.org\/10.1038\/hr.2016.166.","DOI":"10.1038\/hr.2016.166"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_015","doi-asserted-by":"crossref","unstructured":"Judge, C, O\u2019Donnell, M. Low sodium intake increases plasma renin activity. eClinicalMedicine 2021;33:100803. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100803.","DOI":"10.1016\/j.eclinm.2021.100803"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_016","doi-asserted-by":"crossref","unstructured":"Baffour-Awuah, B, Man, M, Goessler, KF, Cornelissen, VA, Dieberg, G, Smart, NA, et al.. Effect of exercise training on the renin-angiotensin-aldosterone system: a meta-analysis. J\u00a0Hum Hypertens 2024;38:89\u2013101. https:\/\/doi.org\/10.1038\/s41371-023-00872-4.","DOI":"10.1038\/s41371-023-00872-4"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_017","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell, E, Floras, JS, Harvey, PJ. Estrogen status and the renin angiotensin aldosterone system. Am J Physiol Regul Integr Comp Physiol 2014;307:R498\u2013500. https:\/\/doi.org\/10.1152\/ajpregu.00182.2014.","DOI":"10.1152\/ajpregu.00182.2014"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_018","doi-asserted-by":"crossref","unstructured":"Cagnoni, F, Njwe, CA, Zaninelli, A, Ricci, AR, Daffra, A, D\u2019Ospina, A, et al.. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag 2010;6:549\u201359. Published 2010 Aug 9. https:\/\/doi.org\/10.2147\/vhrm.s11816.","DOI":"10.2147\/VHRM.S11816"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_019","doi-asserted-by":"crossref","unstructured":"Nehme, A, Zibara, K. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection? Hypertens Res 2017;40:903\u20139. https:\/\/doi.org\/10.1038\/hr.2017.65.","DOI":"10.1038\/hr.2017.65"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_020","doi-asserted-by":"crossref","unstructured":"Liu, Z, Jin, L, Zhou, W, Zhang, C. The spectrum of plasma renin activity and hypertension diseases: utility, outlook, and suggestions. J\u00a0Clin Lab Anal 2022;36:e24738. https:\/\/doi.org\/10.1002\/jcla.24738.","DOI":"10.1002\/jcla.24738"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_021","doi-asserted-by":"crossref","unstructured":"Hartman, D, Sagnella, GA, Chesters, CA, Macgregor, GA. Direct renin assay and plasma renin activity assay compared. Clin Chem 2004;50:2159\u201361. https:\/\/doi.org\/10.1373\/clinchem.2004.033654.","DOI":"10.1373\/clinchem.2004.033654"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_022","doi-asserted-by":"crossref","unstructured":"Lash, B, Fleischer, N. Radioimmunoassay of angiotensin I, for estimation of plasma renin activity. Clin Chem 1974;20:620\u20133. https:\/\/doi.org\/10.1093\/clinchem\/20.5.620.","DOI":"10.1093\/clinchem\/20.5.620"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_023","doi-asserted-by":"crossref","unstructured":"Sealey, JE, Laragh, JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med 1975;5:189\u2013202. https:\/\/doi.org\/10.1016\/s0001-2998(75)80033-x.","DOI":"10.1016\/S0001-2998(75)80033-X"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_024","doi-asserted-by":"crossref","unstructured":"Rehan, M, Raizman, JE, Cavalier, E, Don-Wauchope, AC, Holmes, DT. Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem 2015;48:377\u201387. https:\/\/doi.org\/10.1016\/j.clinbiochem.2015.01.003.","DOI":"10.1016\/j.clinbiochem.2015.01.003"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_025","doi-asserted-by":"crossref","unstructured":"Scharp\u00e9, S, Verkerk, R, Sasmito, E, Theeuws, M. Enzyme immunoassay of angiotensin I and renin. Clin Chem 1987;33:1774\u20137. https:\/\/doi.org\/10.1093\/clinchem\/33.10.1774.","DOI":"10.1093\/clinchem\/33.10.1774"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_026","doi-asserted-by":"crossref","unstructured":"Alderman, MH, Cohen, HW, Sealey, JE, Laragh, JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004;17:1\u20137. https:\/\/doi.org\/10.1016\/j.amjhyper.2003.08.015.","DOI":"10.1016\/j.amjhyper.2003.08.015"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_027","doi-asserted-by":"crossref","unstructured":"Carter, S, Owen, LJ, Kerstens, MN, Dullaart, RP, Keevil, BG. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem 2012;49:570\u20139. https:\/\/doi.org\/10.1258\/acb.2012.011186.","DOI":"10.1258\/acb.2012.011186"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_028","doi-asserted-by":"crossref","unstructured":"Goldstein, DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983;5:86\u201399. https:\/\/doi.org\/10.1161\/01.hyp.5.1.86.","DOI":"10.1161\/01.HYP.5.1.86"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_029","doi-asserted-by":"crossref","unstructured":"Bauer, JH. Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications. Drugs Aging 1993;3:238\u201345. https:\/\/doi.org\/10.2165\/00002512-199303030-00005.","DOI":"10.2165\/00002512-199303030-00005"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_030","doi-asserted-by":"crossref","unstructured":"Valensi, P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovasc Diabetol 2021;20:170. Published 2021 Aug 19. https:\/\/doi.org\/10.1186\/s12933-021-01356-w.","DOI":"10.1186\/s12933-021-01356-w"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_031","doi-asserted-by":"crossref","unstructured":"Deary, AJ, Schumann, AL, Murfet, H, Haydock, SF, Foo, RS, Brown, MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J\u00a0Hypertens 2002;20:771\u20137. https:\/\/doi.org\/10.1097\/00004872-200204000-00037.","DOI":"10.1097\/00004872-200204000-00037"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_032","doi-asserted-by":"crossref","unstructured":"Dickerson, JE, Hingorani, AD, Ashby, MJ, Palmer, CR, Brown, MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008\u201313. https:\/\/doi.org\/10.1016\/s0140-6736(98)07614-4.","DOI":"10.1016\/S0140-6736(98)07614-4"},{"key":"2026033013262434951_j_cclm-2025-1361_ref_033","unstructured":"Hypertension in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE).2023. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547161\/."}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1361\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1361\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:26:44Z","timestamp":1774877204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1361\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,4,24]]}},"alternative-id":["10.1515\/cclm-2025-1361"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-1361","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}